Medical Education in Hematological Malignancies
Medical Education in Hematological Malignancies
For over 20 years, Johnson & Johnson has been dedicated to progressing the treatment of people diagnosed with blood cancers. With more than three decades of continued innovation in oncology, our commitment to pioneer new therapeutic advances and continue redefining treatment paradigms in hematology is stronger than ever.
Through our collaboration with patients, caregivers, and healthcare professionals — including leading specialists — we are advancing science to make transformative care a reality. Our medical education platform provides the latest resources, clinical insights, and tools to support informed decision-making with the aim of improving patient outcomes.
.png?width=1920&height=540&format=webp&quality=50)
EHA 2025 Congress
12–15 June 2025 | Milan, Italy
At EHA 2025, our sessions focused on two areas of hematological malignancies: multiple myeloma (MM) and chronic lymphocytic leukaemia (CLL).
For MM, our expert faculty, including Prof. Maria-Victoria Mateos, Dr. Roberto Nina, Prof. Hermann Einsele, and Prof. Michel Delforge, explored the evolving definitions of cure in MM and how personalised, goal-driven approaches are transforming patient outcomes.
For CLL, our expert faculty, including, Prof. Ruth Clifford, Dr. Jose-Angel Hernandez-Rivas, Dr. Alessandra Tedeschi, Dr. Talha Munir, and Prof. Martin Trepel, gave insights into personalising CLL treatment decisions and factors to consider when choosing between fixed-duration and continuous therapy.
Watch the sessions below
Staying CURE-ious:
Is there a road to cure in 2025 and beyond?
Experts explore the evolving definitions of cure and functional cure in MM and how personalised, goal-driven treatment strategies can optimise outcomes and recognise the potential of emerging therapies
Staying CURE-ious:
Translating multiple myeloma guidelines into clinical practice
Experts provide insight into tailoring treatment for patients with NDMM, identifying candidates for CAR-T at first relapse, and optimising and managing T cell-redirecting therapies
Leveraging efficacy, balancing safety:
Multi-dimensional decision-making in the fixed-duration therapy era of CLL
Experts highlight how data-driven strategies can be used to individualise CLL treatment, helping HCPs choose between fixed-duration and continuous therapy based on efficacy, safety, and patient factors
Featured Hematological Malignancies Events
J&J is proud to be present at key hematology meetings throughout 2026 and 2027.
12–14 February 2026 | Palma de Mallorca, Spain
EBMT CAR T-Cell 2026
22–25 March 2026 | Madrid, Spain
EBMT 2026
16–18 April 2026 | Prague, Czech Republic
EMN 2026
14–17 May 2026 | Paris, France
COMy 2026
11–14 June 2026 | Stockholm, Sweden
EHA 2026
7–12 June 2026 | Boston, Massachusetts, USA
IMS 2026
Date not yet announced | Seoul, South Korea
ICML 2026
17–20 September 2027 | Long Beach, California
XXII iwCLL 2027
Recently Added
Explore the latest educational content on our website, featuring expert-led sessions, insights from KOLs, and practical tools designed to support your continuous learning and enhance your clinical practice.
ICML 2025
From first-line to relapse: the changing landscape of treatment decisions for patients with MCL
From first-line to relapse: the changing landscape of treatment decisions for patients with MCL
An expert panel explore the evolving role of BTK inhibitors in MCL, highlighting evidence-based strategies for 1L and R/R treatment decisions
XXI iwCLL 2025
From data to clinical decisions: Selecting the optimal FDT for 1L CLL patients
From data to clinical decisions: Selecting the optimal FDT for 1L CLL patients
An expert panel provides insights into key efficacy and safety data for fixed duration treatment (FDT) options for 1L CLL and tools for how to select the optimal FDT for patients through a personalised approach
Key Highlights
.png?width=524&height=393&format=webp&quality=50)
Advancing Opinion Leaders (AOL) Meeting
The inaugural Advancing Opinion Leaders (AOL) meeting, held in November 2025 in Prague, Czech Republic, brought together emerging key opinion leaders from across the EMEA region, for an engaging two-day program focused on the latest clinical developments and to discuss and debate practice-changing data.
Check back soon for updates on our 2026 plans - right here on the JJMC.
.png?width=524&height=393&format=webp&quality=50)
EHA 2026
Johnson & Johnson at EHA 2026: Leading with purpose
J&J are proud to be the number one sponsor of the 2026 European Hematology Association Congress - reflecting our commitment to transforming care for people living with blood cancer.
Our presence at EHA showcases our scientific innovation, strong partnerships, and continued progress towards redefining what's possible in hematology.
Introducing J&J withMe
A patient-centric platform designed to support patients throughout their healthcare journey. It provides personalised, high-quality content and services to enhance patient engagement.
By empowering informed, proactive patients, J&J withMe helps improve treatment outcomes.
Learn how this platform can strengthen your patient relationships — explore J&J withMe today!
Our Commitment
Therapeutic Areas
Our scientists and researchers are pioneering the path from lab to life and championing patients each step of the way.
Expert-Driven Education
Our educational programs are developed and reviewed in partnership with a global network of healthcare leaders.
Our Partnerships
We are committed to partnering with medical societies to enhance healthcare outcomes and foster professional education.
Connecting Scientific Expertise
Supporting healthcare professionals to engage in ongoing discussions about the latest scientific advancements.
Our Responsibility to Medical Education
Stay in Touch
We value your connection. Sign up to stay informed about the latest educational resources, and updates. By subscribing, you'll receive timely notifications and exclusive content tailored to your interests.
Contact us
To report an Adverse Event (medication side effect) or a Product Quality Complaint (an issue with one of our products), please select the appropriate link from the Contact dropdown menu. To submit a medical information request, choose the Medical Information page.
Abbreviations
1L, first-line; 4L, fourth-line; BTK, Bruton's tyrosine kinase; CLL, chronic lymphocytic leukaemia; COMy, Controversies in Multiple Myeloma; EBMT, European Society for Blood and Marrow Transplantation; EHA, European Hematology Association; EMEA, Europe, the Middle East, and Africa; EMN, European Myeloma Network; HCPs, healthcare professionals; ICML; International Conference on Malignant Lymphoma; IMS, International Myeloma Society; iwCLL, International Workshop on Chronic Lymphocytic Leukemia; KOLs, key opinion leaders; MM, multiple myeloma; NDMM, newly diagnosed multiple myeloma; R/R, relapsed/refractory.CP-554826 - December 2025
Janssen Pharmaceutica NV